Parkinson’s disease represents an urgent unmet medical need

Global patient population set to more than double from 9 million to 25 million by 2050

In western developed countries, 2-3% of people can expect to receive a diagnosis

Recent studies have estimated the cost of Parkinson’s in the US alone is $82.2 billion in 2024, with projections suggesting it could be as much as $112 billion by 2045

Significantly underfunded (current estimates indicate 10x more funding for Alzheimer’s)

Scientific breakthroughs have created the potential for disruptive new treatments and companies

Dedicated Investment Strategy

Early-stage investments (initial focus on Seed to Series B opportunities)

Global investment remit (initial focus on Europe and North America) 

Development of new treatments for Parkinson’s and related conditions

Contact us : felicity.percy@parkinsonspioneerfund.com arthur.roach@parkinsonspioneerfund.com